argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 mrt 2016 - 07:00
Statutaire naam
argenx SE
Titel
argenx reports fourth quarter business update and full year 2015 financial results
Bericht
Clinical programs in severe auto-immune diseases and oncology
supported by strong financial position
Management to host conference call today at 3 pm CET / 9 am EDT
11 March 2015
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its fourth quarter business update and full year results for 2015, in accordance with IFRS as adopted by the European Union.
Datum laatste update: 09 mei 2025